These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Effect of SGLT-2 inhibitors on cardiovascular outcomes in heart failure patients: A meta-analysis of randomized controlled trials. Lu Y, Li F, Fan Y, Yang Y, Chen M, Xi J. Eur J Intern Med; 2021 May; 87():20-28. PubMed ID: 33824055 [Abstract] [Full Text] [Related]
4. Cardiovascular Outcomes with SGLT-2 inhibitors in patients with heart failure with or without type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Singh AK, Singh R. Diabetes Metab Syndr; 2021 May; 15(1):351-359. PubMed ID: 33503584 [Abstract] [Full Text] [Related]
7. Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: a real-world nationwide population-based cohort study. Kim YG, Han SJ, Kim DJ, Lee KW, Kim HJ. Cardiovasc Diabetol; 2018 Jun 23; 17(1):91. PubMed ID: 29935543 [Abstract] [Full Text] [Related]
11. Sodium Glucose Cotransporter 2 Inhibitors Reduce the Risk of Heart Failure Hospitalization in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Zhang A, Luo X, Meng H, Kang J, Qin G, Chen Y, Zhang X. Front Endocrinol (Lausanne); 2020 Jun 23; 11():604250. PubMed ID: 33519713 [Abstract] [Full Text] [Related]
12. Sodium-glucose cotransporter-2 Inhibitors in Heart Failure: An Updated Systematic Review and Meta-analysis of 13 Randomized Clinical Trials Including 14,618 Patients With Heart Failure. Shrestha DB, Budhathoki P, Sedhai YR, Karki P, Gurung S, Raut S, Damonte JI, Del Buono MG, Mojadidi MK, Elgendy IY, Patel T, Patel NK. J Cardiovasc Pharmacol; 2021 Oct 01; 78(4):501-514. PubMed ID: 34269700 [Abstract] [Full Text] [Related]